A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05625412
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986360 — DRUG
    Specified dose on specified days
  • Docetaxel — DRUG
    Specified dose on specified days
  • Nivolumab — DRUG
    Specified dose on specified days
  • Capecitabine — DRUG
    Specified dose on specified days

Study Details

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.

Key Dates

Start date
Dec 9, 2022
Status verified
Jun 2025
Primary completion
May 12, 2025
Completion
May 12, 2025

Study Design

Enrollment
70 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: BMS-986360
  • Experimental: BMS-986360 + Docetaxel
  • Experimental: BMS-986360 + Nivolumab
  • Experimental: BMS-986360 + Capecitabine

Primary Outcome Measure

Number of participants with Adverse Events (AEs) [ Time Frame: Up to approximately 2 years ]

Locations (8)

FacilityCityStateZIPSite coordinators
Local Institution - 0029Los AngelesCalifornia90025-
Local Institution - 0051Los AngelesCalifornia90067-
Local Institution - 0026New OrleansLouisiana70121-
Local Institution - 0001HackensackNew Jersey07601-
Local Institution - 0018HuntersvilleNorth Carolina28078-
Local Institution - 0028NashvilleTennessee37203-
Local Institution - 0027San AntonioTexas78229-
Local Institution - 0046West Valley CityUtah84119-

Find similar trials in Los Angeles, CA

Related Studies